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To better define important cell subsets expressing activa-
tion markers in rheumatoid arthritis (RA), we compared
selective lymphocyte and monocyte B7H1, B7H2, B7RP.1,
B7RP.2, and inducible costimulatory molecule (ICOS)
expression from normal peripheral blood (NL PB), RA PB,
and RA synovial fluid (SF) by multicolor flow cytometry
and immunohistochemistry. RA SF memory lymphocytes
expressed B7RP.1 and B7RP.2, suggesting that T-cells may
function as antigen presenting cells (APCs) in RA joints.
We found similar results for ICOS expression. RA SF
CD141 monocytes also expressed B7RP.1 (an ICOS
ligand) and the homologous ligand B7RP.2, identifying
monocytes as potential mediators of antigen processing
and lymphocyte activation in RA. Furthermore, we found
an increased population of RA SF CD141 monocytes
expressing B7H1 and B7H2. [The FACS analysis was sup-
ported by immunohistochemistry, showing intense lym-
phocyte and APC (macrophages with dendritic morphol-
ogy) ICOS staining in RA synovial tissue (ST). Overall,
these results define elevated populations of memory
T-lymphocytes expressing proinflammatory B7 molecules
in RA SF that either stimulate T cells through ICOS (via
ICOS ligands B7RP.1 and B7RP.2), or down-regulate RA ST
T-lymphocytes through B7H1 and B7H2.] Therefore, in
the same joint, there may exist positive and negative influ-
ences on the inflammatory response, and perhaps, the
negative signals dominate as joint inflammation resolves.
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The inducible costimulatory molecule (ICOS) is a T-cell
associated receptor involved in cell activation that is con-
servatively expressed on memory T-cell subsets (1). ICOS
is a 60 kDa, disulfide-linked, glycosylated homodimer (1)
expressed on T-lymphocytes in lymphoid organs, such as
spleen, lymph node, and Peyers patches in both humans
and mice (1–5). ICOS expressing T cells are also found in
germinal centers that are enhanced after immune priming
(1,5). ICOS performs several functions in immune activa-
tion including binding B7 accessory molecules on antigen
presenting cells (APCs). This binding results in activation
of responding lymphocytes (1,3). Because they activate
T-cells, ICOS and T-lymphocyte associated molecules,
CTLA4 and CD28, have been designated as potential thera-
peutic targets to treat inflammatory diseases. Akin to
ICOS, CD28 and CTLA4 are quite unique in that these
molecules better define immune function. For example,
B7 ligands found on dendritic cells (and on B-lymphocytes
and monocytes) bind to both T-cell associated CD28 (acti-
vating) and CTL4 (inhibitory) cell receptors. After engage-
ment of antigen and accessory molecules by the T-cell re-
ceptor (TCR), B7 ligands will direct T-cell responses (1).
Therefore, cell-mediated immunity continues unimpeded
or is attenuated depending upon which TCR is bound.
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Interestingly, expression of ICOS on T lymphocytes
depends upon TCR and CD28 signaling mechanisms. Acti-
vation of T cells without CD28 engagement results in
diminished levels of T-cell ICOS expression (1,6). Although
complex, this elegant system ensures that immune
responses are turned on or off appropriately. This process
has been demonstrated in vivo in a murine model of
experimental allergic encephalomyelitis (EAE) in which
it was shown that ICOS protein and mRNA levels were
upregulated on infiltrating CD31 T-cells directly before
disease onset (7). ICOS blockade during the efferent
immune response (9–20 days after immunization) abro-
gated EAE development (7). This finding was supported
in murine collagen induced arthritis (CIA) in which block-
ing B7 and ICOS interactions significantly ameliorated joint
inflammation (8). It was also reported that ICOS gene defi-
cient mice bred on the CIA susceptible DBA-1 background
were completely resistant to CIA development, joint in-
flammation, and proinflammatory cytokine expression (9).
The data presented in this study extend and clarify the
expression of ICOS and B7 costimulatory molecules in
rheumatoid arthritis (RA). We define the expression of
ICOS, B7H1, B7H2, B7RP.1, and B7RP.2 on CD141 mono-
cytes, and on naive (CD45RA1) and memory (CD45RO1)
lymphocytes from normal (NL) peripheral blood (PB), RA
PB, and RA synovial fluid (SF) by flow cytometry. We fur-
ther show by immunohistochemistry that the ligands for
ICOS, namely B7RP.1 and its homologous ligand B7RP.2,
are prominently expressed on RA synovial tissue (ST) mac-
rophages, whereas RA ST lymphocytes express ICOS. This
data indicates that lymphocyte ICOS expression, and the
macrophage associated ligands B7RP.1 and B7RP.2 are
expressed in RA, and may be responsible, at least in part,




SF samples were obtained during arthrocentesis from
patients with RA, and PB was collected in heparinized
tubes from patients with RA or from healthy NL volun-
teers. STs from RA patients were obtained from patients
undergoing total joint replacement who met the American
College of Rheumatology criteria for RA.
Flow Cytometry
SF cells were collected by passing RA SF through a
40 lm nylon mesh filter. Filtered SF was centrifuged, leav-
ing a cell pellet. RA SF cells were washed 33 in FACS
buffer [PBS/1% fetal bovine serum (FBS)] and resuspended
at a concentration of 1 3 107 cells/ml in blocking buffer
(1% BSA/0.1% NaN3/30% goat serum in PBS) for 15 min at
4C. SF cells (1 3 106 per tube) or 100 ml of whole blood
were incubated with primary antibodies directed against
ICOS, B7H1, B7H2, B7RP.1, and B7RP.2 or appropriate IgG
isotype controls (Sigma, St. Louis, MO) at 5 mg/ml in
blocking buffer for 30 min at 4C. Cells were washed with
FACS buffer, then incubated with goat anti-mouse IgG R-
phycoerythrin (PE; Jackson Immunoresearch Laboratory,
West Grove, PA) diluted 1:100 in blocking buffer for 30
min at 4C. Cells were washed and incubated with 20 ll
mouse serum for 10 min at room temperature (RT).
Cychrome-conjugated CD3 (detects T cells) mAbs (Phar-
Mingen, San Diego, CA) were added for 30 min at 4C.
We evaluated ICOS or B7 costimulatory receptor family
expression on naive or memory leukocytes by incubating
cells with either FITC-labeled mouse anti-human CD45RA
(PharMingen, San Diego, CA), which detects naive leuko-
cytes, or mouse anti-human CD45RO (PharMingen, San
Diego, CA), which detects memory leukocytes. SF cells
were washed 23 in FACS buffer and fixed in 500 ll of
fresh 1% formaldehyde in PBS. Whole blood RBCs
were lysed with Becton-Dickinson Lysing Reagent (Becton-
Dickinson, Mountain View, CA) before fixation. ICOS and
B7 expression on lymphocytes and monocytes was deter-
mined by first gating on cells using side scatter properties.
Receptor expression on cells was determined by a second
histogram of the gated CD31 lymphocytes (FITC) or
CD141 monocytes (FITC) against ICOS or B7 molecule
expression (PE) fluorescence. For some studies, chemo-
kine receptor expression on lymphocyte subsets was eval-
uated by incubating cells with anti-CD4-ECD or anti-CD8-
ECD labeled antibodies (Beckman-Coulter, Miami, FL),
added along with FITC (anti-CD45RA or anti-CD45RO)
and cychrome (anti-CD3, PharMingen, San Diego, CA) la-
beled antibodies, using additional histograms to evaluate
memory or naive CD31/CD41 and CD31/CD81 positive
lymphocytes. Cells were analyzed using a Coulter Epics
XL flow cytometer (Coulter, Hialeah, FL) and the percen-
tages of positive cells determined. The numbers of cell
analysis counts were routinely between 75,000 and
200,000 events per tube, depending on the experiment,
with 1 3 106 cells per tube for all experiments. Percen-
tages of cells expressing ICOS or a particular B7 costimula-
tory molecule were calculated after defining a background
value for the isotype matched control antibody.
Immunohistochemistry
Frozen RA ST sections (7 lm) were cut and immunoper-
oxidase stained with an avidin-biotin technique (Vector
Laboratories, Burlingame, CA) with all subsequent incuba-
tions being performed at 37C in a humidified chamber.
Slides were fixed in cold acetone for 20 min, then treated
with 3% peroxidase in 0.1 M Tris for 5 min to block endog-
enous peroxidase activity. Tissues were blocked with 3%
horse serum (in PBS) for 1 h, then incubated with mouse
10 lg/ml anti-human antibody (Millennium Pharmaceuti-
cals, Cambridge, MA), or purified nonspecific mouse anti-
body negative control (Coulter, Miami, FL) for an addi-
tional hour. Antibodies against ICOS, B7H1, B7H2, B7RP.1,
and B7RP.2 (Millennium Pharmaceuticals, Cambridge, MA)
were made as previously described (10). Tissue was
washed twice in PBS, and a 1:200 dilution (in PBS) of anti-
mouse biotinylated antibody (Vector Laboratories, Burlin-
game, MA) was added to the tissue sections and incubated
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for an additional 20 min. After a final washing (23 in
PBS), slides were developed with a diaminobenzidine
tetrahydrochloride substrate (Vector Laboratories) for 2
min at RT, rinsed in tap water, counter-stained with Harris’
Hematoxylin, and dipped in saturated lithium carbonate
solution for bluing.
[Serial tissue sections were examined by a blinded pa-
thologist to determine the percentage of each cell type
expressing B7 molecules in NL and RA ST. Various ST cell
types were identified including macrophages, lympho-
cytes, fibroblasts, endothelial cells, and APCs with dendri-
tic morphology (referred to as dendritic-like cells) by
immunohistochemical staining reaction and/or morpho-
logical features. Human macrophages were identified mor-
phologically and with anti-LeuM5 (Becton Dickinson, San
Jose, CA) and were CD681 (CD68 stain is clone EBM-11,
Dako, IgG1, Carpinteria, CA) in serial sections. Endothe-
lium was verified using anti-von Willebrand’s factor (Dako,
Carpinteria, CA). Dendritic-like cells were identified with
a dendritic cell marker (OX-62 IgG, PharMingen, San
Diego, CA) as previously described (11). Immunostaining
was graded by a frequency of staining scale (0–100%),
where 0% indicated no staining and 100% showed that
all the cells were immunoreactive for each of the ST
components.]
Statistics
PB and SF samples were analyzed by the Student’s inde-
pendent t test. Comparisons of values where P < 0.05
were considered to indicate statistical significance. Error
bars on graphs represent the standard error of the mean.
RESULTS
Flow Cytometry Analysis of CD31 Lymphocytes
in NL PB, RA PB, and RA SF
Two color FACS analysis of CD31 lymphocyte popu-
lations obtained from NL PB, RA PB, and RA SF for
ICOS and B7 molecule expression is shown in Figure 1.
FACS analysis revealed a significant CD31 lymphocyte
population in RA SF expressing B7RP.1 and B7RP.2
compared to lymphocyte populations in NL or RA PB
(Fig. 1).
Four-Color Flow Cytometry Analysis of Naive
CD45RA1/CD31/CD41 and CD45RA1/CD31/CD81
Lymphocyte Subsets in NL PB, RA PB, and RA SF
We preformed FACS analysis of ICOS, B7RP.1, B7RP.2,
B7H1, and B7H2 expression on naive CD45RA1/CD31/
CD41 and CD45RA1/CD31/CD81 lymphocytes from
NL PB, RA PB, and RASF. This is highlighted in Figure 2,
where it is clear that na€ıve CD45RA1/CD31/CD41 lym-
phocytes did not significantly express either ICOS or B7
molecules in any of the patient fluids examined (Fig. 2A,
upper panel), with groups showing the percentage of
expression under 1%. Figure 2B (lower panel) shows the
FACS analysis for CD45RA1/CD31/CD81 lymphocytes in
which expression of ICOS and B7 costimulatory mole-
cules were all relatively low for all groups, lacking statisti-
cal significance for ICOS and B7 molecules examined
between the NL PB, RA PB, and RA SF groups. The lack of
ICOS and B7 molecule expression on CD31/CD41/
CD45RA1 and CD31/CD81/CD45RA1 lymphocytes is
not surprising since we typically do not find large popula-
tions of na€ıve lymphocytes in RA SF on whom inflamma-
tory markers such as chemokine receptors are usually
expressed (10).
[It should be noted that the percentages of na€ıve T-cells,
including CD3/CD4 and CD3/CD8 are low in the RA
SF, but higher in the RA and NL PB. Specifically, T-cells
carrying the CD45RA1 or CD45RO1 phenotypes are
30–40% in the NL and RA PB, however, only 10% of
na€ıve T-cells compared to 40% of activated T-cells are in
the RA SF (10). This is presumably a result of the inflam-
matory environment of the RA joint activating local T-cell
populations.]
Four-Color Flow Cytometry Analysis of Memory
CD45RO1/CD31/CD41 and CD45RO1/CD31/
CD81 Lymphocyte Subsets in NL PB, RA PB,
and RA SF
Figure 3A (upper panel) shows the overall results of
memory lymphocyte CD45RO1/CD31/CD41 ICOS,
B7RP.1, B7RP.2, B7H1, and B7H2 expression from NL PB,
RA PB, and RA SF. As shown, the percentages of B7RP.1
and B7RP.2 expressing lymphocytes were significantly ele-
vated in RA SF compared to NL PB and RA PB; whereas no
significant differences were found in the groups expres-
sing B7H1 or B7H2.
Figure 3B shows the population of memory CD45RO1/
CD31/CD81 ICOS, B7RP.1, B7RP.2, B7H1, and B7H2
FIG. 1. Percentages of CD31 lymphocytes from PB (ICOS n 5 4;
B7RP.1 n 5 4; B7RP.2 n 5 4; B7H1 n 5 4; B7H2 n 5 4), RA PB (ICOS n 5
5; B7RP.1 n 5 4; B7RP.2 n 5 4; B7H1 n 5 4; B7H2 n 5 4), and RA SF
(ICOS n 5 8; B7RP.1 n 5 7; B7RP.2 n 5 7; B7H1 n 5 7; B7H2 n 5 6).
Note the increased populations of B7RP.1 and B7RP.2 expressing CD31
lymphocytes in RA SF compared to NL and RA PB (n, number of different
patients).
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expressing lymphocytes from NL PB, RA PB, and RA SF.
No significant statistical differences were seen with
CD45RO1/CD31/CD81 and any of the other groups
examined. Figure 4 is a representative dot-plot of
CD45RO1/CD31/CD41 lymphocytes from the various
patient SFs. As shown in the dot-plots, large memory
CD31/CD41 lymphocyte populations from the RA SF
expressed both ICOS and the ICOS ligands B7RP.1 and
B7RP.2.
Flow Cytometry Analysis of Memory CD14
Monocytes in NL PB, RA PB, and RA SF
CD14 monocyte expression of ICOS, B7RP.1, B7RP.2,
B7H1, and B7H2 was analyzed by FACS analysis and the
results are shown in Figures 5 and 6. As shown in Figure
5, an increased population of CD141 monocytes expres-
sing ICOS, B7RP.1, B7RP.2, B7H1, and B7H2 is seen in RA
SF compared to both NL and RA PB. Figure 6 is a represen-
tative dot-plot showing the significantly elevated popula-
tions of RA SF CD141 monocytes expressing B7 mole-
cules as well as ICOS. Thus, APCs express B7 molecules
and ICOS in RA SF, but PB CD141 monocytes do not.
Immunohistochemistry of RA ST for ICOS
and B7H2 Expression
[Figure 7 shows a photomicrograph of RA ST immuno-
stained for ICOS. As indicated (see arrows), lymphocytes
are immunoreactive for ICOS. As seen in Figure 8, RA ST
dendritic-like cells were also intensely immunoreactive for
B7H2. Immunoreactive leukocytes were blindly identified
by morphological features by a pathologist (magnification
4003). Table 1 outlines cellular expression of B7H1,
B7H2, B7RP.1, and B7RP.2 in RA and NL ST. As indicated,
only B7H2 dendritic-like cell expression was significantly
elevated in RA ST compared to NL ST.]
FIG. 2. Comparisons of the number of na€ıve CD45RA1/CD31/CD41
lymphocytes from NL PB (ICOS n 5 4; B7RP.1 n 5 4; B7RP.2 n 5 4; B7H1
n 5 4; B7H2 n 5 4), RA PB (ICOS n 5 5; B7RP.1 n 5 4; B7RP.2 n 5 4;
B7H1 n 5 4; B7H2 n 5 4), and RA SF (ICOS n 5 8; B7RP.1 n 5 7; B7RP.2
n 5 7; B7H1 n 5 7; B7H2 n 5 7; upper panel) and CD45RA1/CD31/
CD81 lymphocytes from NL PB (ICOS n 5 4; B7RP.1 n 5 4; B7RP.2 n 5
4; B7H1 n 5 4; B7H2 n 5 4), RA PB (ICOS n 5 5; B7RP.1 n 5 4; B7RP.2
n 5 4; B7H1 n 5 4; B7H2 n 5 4), and RA SF (ICOS n 5 8; B7RP.1 n 5 7;
B7RP.2 n 5 7; B7H1 n 5 7; B7H2 n 5 7; lower panel) is shown. Popula-
tions of na€ıve CD31/CD41 or CD31/CD81 lymphocytes expressing
either ICOS or B7 molecules were only slightly above background for all
groups in NL PB, RA PB, and RA SF (n, number of different patients).
FIG. 3. Comparisons of the number of memory CD45RO1/CD31/
CD41 lymphocytes from NL PB (ICOS n 5 4; B7RP.1 n 5 4; B7RP.2 n 5
4; B7H1 n 5 4; B7H2 n 5 4), RA PB (ICOS n 5 5; B7RP.1 n 5 4; B7RP.2
n 5 4; B7H1 n 5 4; B7H2 n 5 4), and RA SF (ICOS n 5 6; B7RP.1 n 5 7;
B7RP.2 n 5 7; B7H1 n 5 7; B7H2 n 5 7; upper panel) and CD45RO1/
CD31/CD81 lymphocytes from NL PB (ICOS n 5 4; B7RP.1 n 5 4;
B7RP.2 n 5 4; B7H1 n 5 4; B7H2 n 5 4), RA PB (ICOS n 5 5; B7RP.1 n 5
4; B7RP.2 n 5 4; B7H1 n 5 4; B7H2 n 5 4), and RA SF (ICOS n 5 8;
B7RP.1 n 5 7; B7RP.2 n 5 7; B7H1 n 5 7; B7H2 n 5 7; lower panel) is
shown. Populations of memory CD31/CD41, but not CD31/CD81 lym-
phocytes expressing ICOS and the ICOS ligands B7RP.1 and B7RP.2 mole-
cules were elevated in RA SF compared to NL and RA PB (P < 0.05, n,
number of different patients). Thus, RA SF CD31 lymphocyte popula-
tions expressing B7RP.1 and B7RP.2 molecules in Figure 1 were likely
memory CD45RO1/CD31/CD41 lymphocytes. This indicates that infil-
trating memory lymphocytes may be induced to express antigen present-
ing accessory molecules and that these lymphocyte populations may par-
ticipate in antigen processing in the RA joint.
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FIG. 4. Representative histograms (dot plots) showing ICOS, B7H1, B7H2, B7RP.1, and B7RP.2 expression on memory CD45RO1/CD31/CD41 lympho-
cytes. As shown, significant populations of memory CD31/CD41 lymphocytes expressing ICOS, and the ICOS ligands B7RP.1, and B7RP.2 were found in
the RA SF, but not NL or RA PB. NL, normal; PB, peripheral blood; SF, synovial fluid.
DISCUSSION
RA is an autoimmune disease of unknown etiology asso-
ciated with increased angiogenic activity (12–14), and cel-
lular recruitment to the joints (10,11,15,16). Inflammatory
responses in the RA joint can be attributed in large part to
activated T-cells in the RA ST and SF (17). T-cells become
further activated via their constituitively expressed CD28
receptors when presented with antigen from an APC,
along with appropriate signals from APC accessory mole-
cules like B7.1 and B7.2. These interactions are known to
provide potent proinflammatory signals to T-cells, result-
ing in autocrine IL-2 production, which is important for T-
lymphocyte proliferation (1,3,5,18–21). Importance of
CD28 costimulation has been directly demonstrated by
blocking CD28 and B7 interactions and preventing T-cell
responses in autoimmune disease models. In some cases,
this has resulted in prolonged tissue acceptance in organ
transplant models (1,22).
The newest members of the B7 family, namely B7H1,
B7H2, B7RP.1, and B7RP.2, have several distinctive fea-
tures including expression on B lymphocytes (23), and
broader expression in nonlymphoid tissues (24). How-
ever, B7 molecule family members have also been shown
to serve contrasting functions in immunology. For exam-
ple, B7H1 and B7H2, also known as PD-L1 (program death
ligand 1) and PD-L2, respectively, are known to be
expressed on B cells and dendritic cells. They are also
expressed on monocytes that deliver key lymphocytic ap-
optotic signals by engaging the PD-1 receptor on activated
T-lymphocytes, thus attenuating certain immune
responses (1). Conversely, ICOS is an activation marker
expressed on activated T-cells that binds B7RP.1 expres-
sing monocytes. ICOS engagement with B7RP.1, along
with an appropriate antigen, is believed to induce critical
activation signals to the T-cell that exacerbate the
response (1). This process implicates the antigen, along
with an appropriate APC signal, to dictate how activated
T-cells will respond. This produces a biased Type 1 (Th1)
or Type 2 (Th2) cytokine mediated response that triggers
associated chemokine secretion and selective cell recruit-
ment to inflammatory sites (25).
Interestingly, ICOS engagement also augments induc-
tion of both Type 1 and Type 2 cytokines, indicating its
importance in both polarized Type 1 and Type 2 inflam-
matory reactions. Correspondingly, Type 1 and Type 2
cytokines can also influence ICOS expression on numer-
ous cell subsets. For example, ICOS expression is upregu-
lated on murine NK cells, where ICOS dependent cytotox-
icity and IFN-g production is observed through the phos-
phoinositide 3-kinase pathway (26). Furthermore, in a
murine model of airway hyperactivity, bronchial lymph
node cell production of IL-10, a Type 2 associated cyto-
kine, is mediated through the ICOS pathway (27). These
studies indicate a strong relationship between ICOS
expression and Type 1 and Type 2 immunity. However,
the latter finding is further supported by a recent report
showing intraperitoneal treatment of mice with anti-ICOS
neutralizing antibodies during the sensitization phase
with ovalbumin results in decreased airway eosinophilia
and IL-5 production (28). Additionally, it has been shown
that type 2 lymphocytes secreting IL-10 have elevated
ICOS expression (29). Thus, Type 1 and Type 2 lympho-
cytes express ICOS, but it is generally acknowledged that
Type 2 lymphocytes express greater amounts of ICOS
than Type 1 cells (1,6,20,21,30). This could explain, in
part, the attenuating effects of blocking ICOS during Type
2 inflammatory reactions. These findings strongly support
the idea that ICOS blockade is a viable therapeutic strat-
egy for targeting anamnestic, allergic type hypersensitivity
reactions.
Because of the noticeably elevated expression of ICOS
on Type 2 cells, it has been questioned whether ICOS
blockade in Type 1 cytokine mediated reactions may
show benefit in tempering Type 1 inflammation. This
notion was recently tested in a Type 1 mediated murine
EAE model in which ICOS blockade markedly reduced
EAE severity (7). Specifically, EAE progression was signifi-
cantly reduced by administering blocking antibodies to
ICOS during the efferent phase of the immune response
(days 9–20), a time when the disease course adopts a
Type 1 profile. Interestingly, anti-ICOS antibody adminis-
tration during the priming phase of EAE (days 0–9) exacer-
bated the disease, likely due to inhibition of an early Type
2 response. Development of this Type 2 reaction may
have naturally tempered a later Type 1 response (7). In
agreement with these findings is a report by Iwai et al.,
showing reduction of murine CIA development, a prototy-
pical Type 1 disease, was achieved by administering neu-
tralizing, anti-B7 antibodies capable of blocking B7 and
ICOS interactions after the boosting (antigen priming)
phase of CIA (8). In agreement, Nurieva et al., showed
ICOS knockout CIA susceptible DBA-1 mice are comple-
tely resistant to CIA development and joint inflammation
(9). Taken together, these results indicate ICOS and B7
FIG. 5. Expression of ICOS and B7 accessory molecules on CD141
monocytes from NL PB (ICOS n 5 5; B7RP.1 n 5 5; B7RP.2 n 5 5; B7H1
n 5 5; B7H2 n 5 4), RA PB (ICOS n 5 4; B7RP.1 n 5 5; B7RP.2 n 5 5;
B7H1 n 5 5; B7H2 n 5 5), and RA SF (ICOS n 5 4; B7RP.1 n 5 4; B7RP.2
n 5 4; B7H1 n 5 3; B7H2 n 5 3). Elevated populations of CD141 mono-
cytes expressing ICOS, the ICOS ligands B7RP.1, B7RP.2, and the PD-1 and
PD-2 ligands B7H1 and B7H2 respectively were found in RA SF compared
to NL or RA PB (P < 0.05, n, number of different patients). This indicates
that monocytes in the RA joint respond to both positive and negative
influences as joint inflammation progresses.
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FIG. 6. Representative histograms (dot plots) showing ICOS, B7H1, B7H2, B7RP.1, and B7RP.2 expression on CD141 monocytes from NL PB, RA PB, and
RA SF. As shown, significant populations CD141monocytes expressing ICOS, and the ICOS ligands B7RP.1, and B7RP.2, as well as the PD-1 and PD-2 ligands
B7H1 and B7H2 respectively were found in RA SF compared to NL and RA PB. NL, normal; PB, peripheral blood; SF, synovial fluid.
molecules may play an integral part in the pathogenesis of
CIA and other Type 1 diseases. These findings also indi-
cate that antagonizing B7-ICOS interactions may be worth-
while in treating RA, assuming these molecules are signifi-
cantly expressed in human RA tissues.
The recent study by Okamota et al. describes ICOS
expression on CD41 RA SF cells, and shows by reverse
transcriptase polymerase chain reaction (RT-PCR) that RA
ST contained elevated mRNA levels of the ICOS ligand
B7RP.1 (31). The data herein further defines upregulated
populations of ICOS expressing cell subsets, including
CD141 monocytes in RA SF. Furthermore, we clearly
demonstrate upregulation of B7 molecules on RA SF
CD141 monocytes, indicating activation of the innate
immune response in RA patients. We also identified 25%
of RA SF memory CD31/CD41 lymphocytes expressing
B7RP-1 or B7RP-2, and 10% of memory CD31/CD41
lymphocytes expressing ICOS. Thus, lymphocytes, as well
as monocytes can express ICOS and B7 molecules in RA
SF compared to NL or RA PB. This is consistent with our
previous study showing T-cells express B7 molecules in
the RA ST (17). It is tempting to speculate that lympho-
cytes and monocytes may swap ICOS and B7 molecules
during antigen presentation in the RA joint, where there is
abundant antigen. This exchange would explain the ele-
vated expression of B7 that allows synovial T cells to serve
as functional APCs in the rheumatoid joint (17). By this
method, functional immune cells could increase or
decrease reactivity in the RA joint via the ICOS and/or
CD28 pathways.
With respect to ICOS expression on cell subsets during
inflammatory responses, the question arises whether
ICOS expressing leukocyte populations are specifically
recruited to the RA joint, or stimulated to express ICOS
upon entering the joint? The latter explanation is unlikely
considering that in vivo interperitoneal blockade of ICOS
FIG. 7. Photomicrograph of RA ST immunostained for ICOS expression. As shown, scattered lymphocytes in the RA ST stained positive for ICOS (indi-
cated as L, see arrows; original magnification 3400). [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
FIG. 8. Photomicrograph of RA ST immunostained for B7H2. As shown, intense B7H2 staining of ST APCs (dendritic-like cells) was found in RA com-
pared to NL ST (indicated as DLC, see arrows; original magnification 3400). [Color figure can be viewed in the online issue, which is available at www.
interscience.wiley.com.]
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before development of inflammation shows marked
effects on EAE development (7). However, it is currently
unknown whether these lymphocyte populations are spe-
cifically recruited to the RA joint by coexpression of che-
mokine receptors. We are currently examining these pos-
sibilities with in vitro multicolor flow cytometry experi-
ments. [Nevertheless, leukocytes do over express ICOS
and B7H2 in RA ST, as immunohistochemical analysis
showed robust staining for lymphocyte ICOS and APC
(dendritic like cell) B7H2 expression.] Interestingly, we
identified B7 molecules on RA SF CD141 monocytes
known to down-regulate T-cell activation through PD-1
(B7H1 and 2), and upregulate T-cell activation through
B7RP.1. [We also show in Table 1 that RA ST associated
dendritic-like cells significantly express B7H2 compared
to NL ST.] Thus, in the same joint, there appear to be both
positive and negative influences, in which positive, proin-
flammatory forces may be dominating as the RA patient
becomes symptomatic. It is also possible that negative
feedback signals begin to dominate as joint inflammation
resolves, for example, due to RA therapy. Thus, leukocytes
bearing ICOS and B7 molecules may be critical mediators
of joint inflammation, partly responsible for the waxing
and waning nature associated with RA.
Overall, these findings suggest that CD31/CD41 mem-
ory lymphocytes, because of upregulated costimulatory
and ICOS molecule expression, are primed for lympho-
cyte recruitment and activation in RA. This data identifies
increased populations of cell subsets expressing B7 mole-
cules and ICOS in RA, and strongly indicates that ICOS
and/or B7 molecule blockade may be a relevant target for
RA treatment.
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Table 1
B7 Molecule Staining in RA and NL Synovial Tissues
Inflm score Vasc (1–4) Line % Macs % EC % SM % Lymph % DC % Fib %
NL ST
B7RP.1
Mean 1 2 38 1 0 0 0 11 0
SEM6 0.0 0.0 21.2 0.8 0.0 0.0 0.0 6.7 0.0
No. of tissues 6 6 6 6 6 6 6 6 6
B7RP.2
Mean 1 2 7 2 0 0 0 18 0
SEM6 0.0 0.2 4.7 0.9 0.0 0.0 0.0 5.0 0.2
No. of tissues 6 6 6 6 6 6 6 6 6
B7H1
Mean 1 2 0 0 0 0 0 12 0
SEM6 0.2 0.2 0.0 0.2 0.0 0.0 0.0 7.2 0.0
No. of tissues 6 6 6 6 6 6 6 6 6
B7H2
Mean 1 2 0 3 0 0 0 13 0
SEM6 0.2 0.3 0.0 3.3 0.0 0.0 0.0 4.8 0.0
No. of tissues 6 6 6 6 6 6 6 6 6
RA ST
B7RP.1
Mean 2 2 36 6 0 0 0 16 1
SEM6 0.3 0.3 20.3 3.0 0.2 0.3 0.0 7.0 0.9
No. of tissues 6 6 6 6 6 6 6 6 6
B7RP.2
Mean 2 2 21 1 0 0 0 15 0
SEM6 0.2 0.0 17.4 1.0 0.0 0.0 0.0 5.3 0.0
No. of tissues 6 6 6 6 6 6 6 6 6
B7H1
Mean 3 3 15 5 0 0 0 6 0
SEM6 0.3 0.3 12.2 4.1 0.0 0.0 0.0 1.4 0.0
No. of tissues 6 6 6 6 6 6 6 6 6
B7H2
Mean 3 3 37 20 0 0 0 46* 1
SEM6 0.2 0.2 20.7 14.1 0.0 0.0 0.0 14.2 1.0
No. of tissues 6 6 6 6 6 6 6 6 6
*P < 0.05 NL ST compared to RA ST.
Inflm score, inflammatory score; Vasc, vascular score; Line, lining cells; Macs, macrophages; EC, endothelial cells; SM, smooth muscle
cells; Lymp, lymphocytes; DC, dendritic-like cells; Fib, fibroblasts.
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